JournalArta
Sunday, November 22, 2026 · JakartaS&P 6,910.39 ▼3.70%USD/IDR 18,158 ▼0.42%
JournalArta
Global Edition
beyond headlines
Advertisement

Regeneron Drug Combination Clears Tumors in Mouse Study

A combination of Enhertu and an experimental antibody eliminated breast tumors in nine mice, Regeneron researchers found. The animals later rejected the same cancer cells without further treatment. The findings do not establish whether the approach is safe or effective in people.

By Elena Vance
WIB2 min read
Regeneron Drug Combination Clears Tumors in Mouse Study
Regeneron Drug Combination Clears Tumors in Mouse Study

Regeneron researchers found that an experimental drug combination eliminated breast tumors in nine mice and helped them reject the same cancer cells later. The results offer evidence of an immune response in mice, but the treatment’s safety and effectiveness in people require further evaluation.

The animals needed no further treatment to reject the cells. They had remained tumor-free for at least four weeks before researchers injected them again with the same cancer.

The combination paired Enhertu, an established cancer drug, with an experimental antibody designed to support immune cells. Researchers at US biotechnology company Regeneron Pharmaceuticals conducted the study, which was published in Nature Communications.

Advertisement

All nine mice lost tumors

In the initial breast cancer tests, Enhertu alone produced complete tumor responses in fewer than half the mice, even at the highest dose tested. All nine mice given Enhertu and the experimental antibody became tumor-free.

Enhertu, also known as trastuzumab deruxtecan, uses an antibody to carry a cell-killing payload. The antibody binds to HER2, a growth-related protein, helping deliver the payload to cells carrying it.

The drug is already used for certain breast, stomach and other cancers, depending on tumor characteristics and previous treatments.

The experimental antibody binds to two targets. One part attaches to a protein on tumor cells; the other engages CD28, an activation protein on immune cells called T cells.

Advertisement

A different colorectal tumor grew in the previously treated mice, although its cells also carried HER2. That suggested the immune response recognized features of the original cancer beyond the shared protein.

Researchers found that removing cancer-killing CD8 T cells completely abolished the initial combination’s benefit. The cells were essential to its success in the experiment.

Other combinations showed activity

The team also combined Enhertu with an experimental antibody targeting EGFR, another growth-related protein. The antibody is already in early-stage human trials.

That combination produced tumor rejection in about 75 percent of mice in a breast tumor model more resistant to Enhertu alone.

Advertisement

The EGFR-targeting antibody also worked with fluorouracil, a chemotherapy drug used for colorectal and other cancers. Together, they slowed colorectal tumor growth when either treatment alone had little effect.

That combination retained some activity when either CD8 T cells or natural killer cells, another cancer-killing population, were absent. Its benefit disappeared when both were missing.

Human safety needs further study

The mouse models cannot reproduce the full range of side effects people may experience, including damage to the lungs, gut, heart and skin. Some combinations remained effective with lower drug doses or less frequent chemotherapy.

Regeneron funded the research. All authors are current or former employees, and provisional patent applications related to the work have been filed.

Advertisement
What Kind of Holiday Spender Are You? Take the Black Friday QuizTake the quizWhat Kind of Holiday Spender Are You? Take the Black Friday QuizStart →
Advertisement
Most Read
  1. 1Magnitude 4.2 Earthquake Wakes Los Angeles Before DawnMagnitude 4.2 Earthquake Wakes Los Angeles Before Dawn
  2. 2Dow Jones Futures Await Reopening After Tech Stocks SlideDow Jones Futures Await Reopening After Tech Stocks Slide
  3. 3Micron Says Memory Has Changed as Shares Fall 13.89%Micron Says Memory Has Changed as Shares Fall 13.89%
  4. 4GTA 6 Draws Review Bombing on MetacriticGTA 6 Draws Review Bombing on Metacritic
  5. 5ORCL Stock Week Ahead: Levels and Scenarios for November 23–27ORCL Stock Week Ahead: Levels and Scenarios for November 23–27
Advertisement
Don't Miss

Latest News

All stories →
  1. Trump Praises China Summit as Leaders Issue Four-Point DeclarationAsia · East AsiaTrump Praises China Summit as Leaders Issue Four-Point DeclarationNov 22
  2. Crypto Sell Setups This Week: JUP, TAO, POL, NEAR Stay Under PressureMarkets · CryptoCrypto Sell Setups This Week: JUP, TAO, POL, NEAR Stay Under PressureNov 22
  3. EU Reaches Deal on Sustainable Investment RulesBusiness · Macro & PolicyEU Reaches Deal on Sustainable Investment RulesNov 22
  4. Brussels Plans European Preference for Quantum ContractsWorld · EuropeBrussels Plans European Preference for Quantum ContractsNov 22
  5. Advertisement
  6. Daniel Andrews Advises Businessman Seeking Data Center DealsWorld · AustraliaDaniel Andrews Advises Businessman Seeking Data Center DealsNov 22
  7. Alice Huang’s Gaming Ties Draw Scrutiny in Chip ProbeBusiness · CompaniesAlice Huang’s Gaming Ties Draw Scrutiny in Chip ProbeNov 22
  8. OpenSanctions barred in Germany from listing Usmanov under EU sanctionsWorld · EuropeOpenSanctions barred in Germany from listing Usmanov under EU sanctionsNov 22
  9. England Faces Flood Warnings in Drought-Hit SouthwestWorld · EuropeEngland Faces Flood Warnings in Drought-Hit SouthwestNov 22